Lentinan-Modified Carbon Nanotubes as an Antigen Delivery System Modulate Immune Response in Vitro and in Vivo
Source abstract
Abstract
Adjuvants enhance immunogenicity and sustain long-term immune responses. As vital components of vaccines, efficient adjuvants are highly desirable. Recent evidence regarding the potential of carbon nanotubes (CNTs) to act as a support material has suggested that certain properties, such as their unique hollow structure, high specific surface area, and chemical stability, make CNTs desirable for a variety of antigen-delivery applications. Lentinan, a β-1,3-glucohexaose with β-1,6-branches that is extracted from the mushroom Lentinus edodes, is an effective immunostimulatory drug that has been clinically used in Japan and China, and recent studies have proved that specific beta-glucans can bind to various immune receptors. In this research, we covalently attached lentinan to multiwalled carbon nanotubes (MWCNTs) and tested their ability to enhance immune responses as a vaccine delivery system. In vitro study results showed that the nanotube constructs could rapidly enter dendritic cells and carry large amounts of antigen. Moreover, maturation markers were significantly upregulated versus the control. Thus, lentinan-modified multiwalled carbon nanotubes (L-MWCNTs) were regarded as an effective intracellular antigen depot and a catalyzer that could induce phenotypic and functional maturation of dendritic cells. Furthermore, compared with L-MWCNTs (35 μg/mL), a corresponding concentration of carboxylic carbon nanotubes (C-MWCNTs, 31.8 μg/mL) and an equivalent concentration of lentinan (3.2 μg/mL) did not remarkably influence the immune reaction in vitro or in vivo. Hence, we can hypothesize that the capability of L-MWCNTs was a consequence of the increased intracellular quantity of lentinan grafted onto the nanotubes. Overall, our studies demonstrated that L-MWCNTs significantly increased antigen accumulation in the cells and potentiated cellular and humoral immunity. In conclusion, L-MWCNTs constitute a potential vaccine delivery system to enhance immunogenicity for therapeutic purposes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Transgenic Plants and Applications · Polysaccharides and Plant Cell Walls · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Traditional Chinese Veterinary Medicine, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, PR China
College of Animal Science and Veterinary Medicine, Fujian Agriculture and Forestry University, Fuzhou 350002, PR China
Funding
Ministry of Agriculture of the People's Republic of China · National Natural Science Foundation of China
References (38)
Show source-provided references
1. 10.1111/j.1600-065X.2007.00552.x10.1111/j.1600-065X.2007.00552.x ↗
2. 10.1038/nri245410.1038/nri2454 ↗
3. 10.1016/j.ijpharm.2008.04.03610.1016/j.ijpharm.2008.04.036 ↗
4. 10.1016/j.vaccine.2007.01.11110.1016/j.vaccine.2007.01.111 ↗
5. 10.3389/fimmu.2013.0040710.3389/fimmu.2013.00407 ↗
6. 10.1016/j.drudis.2011.04.00610.1016/j.drudis.2011.04.006 ↗
7. 10.1016/j.antiviral.2005.02.00110.1016/j.antiviral.2005.02.001 ↗
8. 10.1021/cm102406h10.1021/cm102406h ↗
9. 10.1021/nn200182x10.1021/nn200182x ↗
10. 10.1016/j.chembiol.2003.09.01110.1016/j.chembiol.2003.09.011 ↗
11. 10.1088/0957-4484/22/29/29571210.1088/0957-4484/22/29/295712 ↗
12. 10.1158/0008-5472.CAN-08-146810.1158/0008-5472.CAN-08-1468 ↗
13. 10.1002/anie.20050161310.1002/anie.200501613 ↗
14. 10.1016/j.cbpa.2005.10.00510.1016/j.cbpa.2005.10.005 ↗
15. 10.1021/ja044156110.1021/ja0441561 ↗
16. 10.1039/c0cc02092c10.1039/c0cc02092c ↗
17. 10.1021/nl061160x10.1021/nl061160x ↗
18. 10.1073/pnas.070056710410.1073/pnas.0700567104 ↗
19. 10.1021/ja050062v10.1021/ja050062v ↗
20. 10.1016/j.toxlet.2012.12.00810.1016/j.toxlet.2012.12.008 ↗
21. 10.1021/nn201447910.1021/nn2014479 ↗
22. 10.1039/B911099M10.1039/B911099M ↗
23. 10.1038/nnano.2007.22310.1038/nnano.2007.223 ↗
24. 10.1016/j.biomaterials.2013.02.05210.1016/j.biomaterials.2013.02.052 ↗
25. 10.1016/j.vaccine.2005.02.01110.1016/j.vaccine.2005.02.011 ↗
26. 10.1016/j.antiviral.2007.03.00810.1016/j.antiviral.2007.03.008 ↗
27. 10.1016/0192-0561(82)90127-810.1016/0192-0561(82)90127-8 ↗
28. 10.1007/s00253-002-1076-710.1007/s00253-002-1076-7 ↗
29. 10.1615/IntJMedMushrooms.v1.i1.2010.1615/IntJMedMushrooms.v1.i1.20 ↗
30. 10.1021/ac801118p10.1021/ac801118p ↗
31. 10.1016/j.vaccine.2010.04.04610.1016/j.vaccine.2010.04.046 ↗
32. 10.1021/nl060394d10.1021/nl060394d ↗
33. 10.1016/j.cej.2009.11.02610.1016/j.cej.2009.11.026 ↗
34. 10.1021/ar300031y10.1021/ar300031y ↗
35. 10.1016/j.apsusc.2009.05.01610.1016/j.apsusc.2009.05.016 ↗
36. 10.1021/jp802163410.1021/jp8021634 ↗
37. 10.4049/jimmunol.181.5.306710.4049/jimmunol.181.5.3067 ↗
38. 10.3109/17435390.2010.52348310.3109/17435390.2010.523483 ↗